8,276 Shares in Merit Medical Systems, Inc. (NASDAQ:MMSI) Acquired by Redhawk Wealth Advisors Inc.

Redhawk Wealth Advisors Inc. acquired a new stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 8,276 shares of the medical instruments supplier’s stock, valued at approximately $800,000.

A number of other institutional investors have also recently modified their holdings of MMSI. Park Avenue Securities LLC raised its stake in Merit Medical Systems by 20.6% in the fourth quarter. Park Avenue Securities LLC now owns 4,812 shares of the medical instruments supplier’s stock valued at $465,000 after purchasing an additional 821 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Merit Medical Systems by 79.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 166,927 shares of the medical instruments supplier’s stock valued at $16,145,000 after buying an additional 74,019 shares during the period. Diversified Trust Co raised its position in shares of Merit Medical Systems by 8.7% in the 4th quarter. Diversified Trust Co now owns 12,584 shares of the medical instruments supplier’s stock valued at $1,217,000 after buying an additional 1,008 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Merit Medical Systems by 14.7% during the 4th quarter. GAMMA Investing LLC now owns 1,494 shares of the medical instruments supplier’s stock worth $144,000 after acquiring an additional 191 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Merit Medical Systems by 85.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 575,946 shares of the medical instruments supplier’s stock worth $56,921,000 after acquiring an additional 265,648 shares in the last quarter. 99.66% of the stock is currently owned by institutional investors.

Insider Transactions at Merit Medical Systems

In other news, Director F. Ann Millner sold 12,500 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.55, for a total transaction of $1,269,375.00. Following the completion of the sale, the director now directly owns 32,391 shares in the company, valued at $3,289,306.05. This represents a 27.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Raul Jr. Parra sold 29,646 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the completion of the transaction, the chief financial officer now owns 16,361 shares in the company, valued at approximately $1,603,705.22. The trade was a 64.44 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is owned by corporate insiders.

Merit Medical Systems Trading Up 0.5 %

Shares of NASDAQ MMSI opened at $102.07 on Friday. The firm has a 50 day moving average price of $101.00 and a two-hundred day moving average price of $95.77. The stock has a market cap of $5.95 billion, a P/E ratio of 50.03, a price-to-earnings-growth ratio of 2.15 and a beta of 0.85. Merit Medical Systems, Inc. has a 52-week low of $70.70 and a 52-week high of $108.07. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings data on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. The business had revenue of $339.85 million during the quarter, compared to the consensus estimate of $334.60 million. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. Merit Medical Systems’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.75 earnings per share. As a group, equities analysts forecast that Merit Medical Systems, Inc. will post 3.36 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on MMSI shares. Wells Fargo & Company upgraded Merit Medical Systems from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $103.00 to $120.00 in a research note on Wednesday, December 11th. Barrington Research restated an “outperform” rating and set a $114.00 price objective on shares of Merit Medical Systems in a research report on Monday, December 23rd. StockNews.com cut Merit Medical Systems from a “buy” rating to a “hold” rating in a research report on Sunday, November 3rd. Canaccord Genuity Group increased their target price on shares of Merit Medical Systems from $125.00 to $127.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $109.00 price target on shares of Merit Medical Systems in a report on Tuesday. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $107.70.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.